Facilities for Centralized Isolation and Quarantine for the Observation and Treatment of Patients with COVID-19

Abstract

The coronavirus disease 2019 (COVID-19) pandemic increased the burden on many healthcare systems and in the process, exposed the need for medical resources and physical space. While few studies discussed the efficient utilization of medical resources and physical space so far. Therefore, this study aimed to summarize experiences related to facilities used for centralized isolation for medical observation and
treatment during the COVID-19 pandemic in China and to provide suggestions to further improve the management of confirmed cases, suspected cases, and close contacts. In China, three types of facilities for centralized isolation (Fangcang shelter hospitals, refitted non-designated hospitals, and quarantine hotels) underwent retrofitting for the treatment and isolation of confirmed and suspected cases. These
facilities mitigated the immediate high demand for space. Moreover, in order to minimize infection risks in these facilities, regulators and governmental agencies implemented new designs, management measures, and precautionary measures to minimize infection risk. Other countries and regions could refer to China's experience in optimally allocating social resources in response to the COVID-19 pandemic.
As a conclusion, government should allocate social resources and construct centralized isolation and quarantine facilities for an emergency response, health authorities should issue regulations for centralized isolation facilities and pay strict attention to the daily management of these facilities, a multidisciplinary administration team is required to support the daily operation of a centralized isolation facility, in-depth studies and international collaboration on the centralized isolation policy are encouraged.

Keywords

Centralized isolation / Risk control / Infectious patients / Close contacts / Coronavirus disease

References

[[1]] covid19.who.int [Internet]. Geneva: WHO; 2020 [cited 2020 Oct 9]. Available from: https://covid19.who.int/.

[[2]] Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med 2020;26(4):506–10.

[[3]] Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020;104(3):246–51.

[[4]] Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. Lancet 2020;395 (10233):1382–93.

[[5]] Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase. Int J Infect Dis 2020;92:214–7.

[[6]] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395 (10223):497–506.

[[7]] Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus disease 2019 based on crowdsourced data: a population-level observational study. Lancet Digit Health 2020;2(4):e201–8.

[[8]] Qiu J. Covert coronavirus infections could be seeding new outbreaks. Nature. Epub 2020 Mar 20.

[[9]] WHO. Report of the WHO–China Joint Mission on coronavirus disease 2019 (COVID-19) [Internet]. 2020 [cited 2021 Apr 6]. Available from: https://www. who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19).

[[10]] Pan A, Liu L, Wang C, Guo H, Hao X, Wang Q, et al. Association of public health interventions with the epidemiology of the COVID-19. JAMA 2020;323 (19):1915–23.

[[11]] Greaves WL, Orenstein WA, Stetler HC, Preblud SR, Hinman AR, Bart KJ. Prevention of rubella transmission in medical facilities. JAMA 1982;248 (7):861–4.

[[12]] Kickbusch I, Leung G. Response to the emerging novel coronavirus outbreak. BMJ 2020;368:m406.

[[13]] Khafaie MA, Rahim F. Cross-country comparison of case fatality rates of COVID-19/SARS-CoV-2. Osong Public Health Res Perspect 2020;11(2): 74–80.

[[14]] Tang B, Bragazzi NL, Li Q, Tang S, Xiao Y, Wu J. An updated estimation of the risk of transmission of the novel coronavirus (2019-nCoV). Infect Dis Model 2020;5:248–55.

[[15]] Rosenberger LH, Riccio LM, Campbell KT, Politano AD, Sawyer RG. Quarantine, isolation, and cohorting: from cholera to Klebsiella. Surg Infect 2012;13 (2):69–73.

[[16]] Xie L, Liu Y, Xiao Y, Tian Q, Fan B, Zhao H, et al. Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge. Chest 2005;127(6):2119–24.

[[17]] Xu ZY, Li ZH, Wang JX, Xiao ZP, Dong DX. Ecology and prevention of a shellfishassociated hepatitis a epidemic in Shanghai, China. Vaccine 1992;10(Suppl 1): S67–8.

[[18]] Chen S, Chen Q, Yang W, Xue L, Liu Y, Yang J, et al. Buying time for an effective epidemic response: the impact of a public holiday for outbreak control on COVID-19 epidemic spread. Engineering 2020;6(10):1108–14.

[[19]] Chen S, Zhang Z, Yang J, Wang J, Zhai X, Bärnighausen T, et al. Fangcang shelter hospitals: a novel concept for responding to public health emergencies. Lancet 2020;395(10232):1305–14.

[[20]] Chen S, Chen Q, Yang J, Lin L, Li L, Jiao L, et al. Curbing the COVID-19 pandemic with facility-based isolation of mild cases: a mathematical modeling study. J Travel Med 2021;28(2):taaa226.

[[21]] Lee EC, Wada NI, Grabowski MK, Gurley ES, Lessler J. The engines of SARS-CoV2 spread. Science 2020;370(6515):406–7.

[[22]] Omar S, Bartz C, Becker S, Basenach S, Pfeifer S, Trapp C, et al. Duration of SARS-CoV-2 RNA detection in COVID-19 patients in home isolation, RhinelandPalatinate, Germany, 2020—an interval-censored survival analysis. Eurosurveillance 2020;25(30):2001292.

[[23]] Wilder-Smith A, Cook AR, Dickens BL. Institutional versus home isolation to curb the COVID-19 outbreak—authors’ reply. Lancet 2020;396(10263): 1632–3.

[[24]] Hung KKC, Mark CKM, Yeung MPS, Chan EYY, Graham CA. The role of the hotel industry in the response to emerging epidemics: a case study of SARS in 2003 and H1N1 swine flu in 2009 in Hong Kong. Global Health 2018;14(1):117.

[[25]] Widmer AF. Infection control and prevention strategies in the ICU. Intensive Care Med 1994;20(Suppl 4):S7–11.

[[26]] Fusco FM, Brouqui P, Ippolito G, Vetter N, Kojouharova M, Parmakova K, et al. Highly infectious diseases in the Mediterranean Sea area: inventory of isolation capabilities and recommendations for appropriate isolation. New Microbes New Infect 2018;26:S65–73.

[[27]] Chen S, Yang J, Yang W, Wang C, Bärnighausen T. COVID-19 control in China during mass population movements at New Year. Lancet 2020;395 (10226):764–6.

[[28]] Ding J, Tuan WJ, Temte JL. Managing close contacts of COVID-19 confirmed cases in metropolitan areas in China. J Public Health Manag Pract 2020;26 (4):345–8.

[[29]] Thomas STL, Wai CY. The lessons of SARS in Hong Kong. Clin Med 2010;10 (1):50–3.

[[30]] Chen S, Prettner K, Cao B, Geldsetzer P, Kuhn M, Bloom DE, et al. Revisiting the association between temperature and COVID-19 transmissibility across 117 countries. ERJ Open Res 2020;6(4):00550-2020.

[[31]] Prettner K, Chen SC, Kuhn M, Bloom D. Effective pandemic management that minimises economic harm [Internet]. VoxEU; 2021 Jan 4 [cited 2021 Apr 6]. Available from: https://voxeu.org/article/effective-pandemic-managementminimises-economic-harm.

[[32]] www.who.int [Internet]. Geneva: WHO; 2020 [cited 2020 Oct 9]. Available from: https://www.who.int/news-room/feature-stories/detail/who-chinajoint-mission-on-coronavirus-disease-2019-(covid-19).

[[33]] Tang S, Mao Y, Jones RM, Tan Q, Ji JS, Li N, et al. Aerosol transmission of SARSCoV-2? Evidence, prevention and control. Environ Int 2020;144:106039–47.